Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13851926 | 1.00 | KCNN4 (0.44) | KCNN4CYP1A2CYP2D6CRHBPCRHR2 | |
| SCHEMBL15393649 | 0.82 | TSHR (0.42) | MAOAKIF11 | |
| SCHEMBL16363073 | 0.82 | TSHR (0.42) | MAOAKIF11 | |
| SCHEMBL28351446 | 0.81 | CYP1A2 (0.42) | KCNN4CYP1A2CYP2D6TAAR1SLC6A2 | |
| SCHEMBL28351447 | 0.81 | CYP1A2 (0.42) | KCNN4CYP1A2CYP2D6TAAR1SLC6A2 | |
| SCHEMBL114847 | 0.81 | KCNN4 (0.48) | KCNN4CYP1A2CYP2D6TAAR1SLC6A2 | |
| SCHEMBL16928433 | 0.80 | MAOA (0.38) | KCNN4MAOACYP3A4KIF11 | |
| Ammonia Solution, Strong SCHEMBL1484878 | 0.79 | CYP1A2 (0.41) | KCNN4CYP1A2CYP2D6TAAR1SLC6A2 | |
| SCHEMBL2837925 | 0.77 | SLC6A4 (0.46) | CYP1A2CYP2D6MAOASLC6A4SLC6A3 | |
| SCHEMBL636461 | 0.77 | SLC6A4 (0.46) | CYP1A2CYP2D6MAOASLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311975-A1 | CATIONIC TRANSITION METAL CATALYSTS | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2010-12-09 | — | — | US | claimed |
| EP-2215101-A1 | CATIONIC TRANSITION METAL CATALYSTS | Kanata Chemical Technologies Inc. (CA) | 2010-08-11 | — | — | EP | claimed |
| WO-2009055912-A1 | CATIONIC TRANSITION METAL CATALYSTS | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2009-05-07 | — | — | WO | claimed |
| US-5763688-A | HYDROGENATING A CARBONYL COMPOUND, RUTHENIUM-PHOSPHINE COMPLEX CATALYST, BASE, DIAMINE | RESEARCH DEVELOPMENT CORPORATION OF JAPAN (JP) | 1998-06-09 | — | — | US | claimed |
| US-12129249-B2 | Method for producing optically active compound | DAY ONE BIOPHARMACEUTICALS, INC. (US) | 2024-10-29 | — | — | US | disclosed |
| EP-4406609-A2 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | Day One Biopharmaceuticals, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| CN-117447464-A | Method for producing optically active compound | 首日生物制药公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-111032047-B | Method for producing optically active compound | 多特疗法-1公司 | 2023-10-27 | — | — | CN | disclosed |
| US-20220169600-A1 | METHOD FOR PRODUCING PKROSTAGLANDIN | KYOWA PHARMA CHEMICAL CO., LTD. (JP) | 2022-06-02 | — | — | US | disclosed |
| EP-3950672-A1 | METHOD FOR PRODUCING PKROSTAGLANDIN | Kyowa Pharma Chemical Co., Ltd. (JP) | 2022-02-09 | — | — | EP | disclosed |
| US-20210347769-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DAY ONE BIOPHARMACEUTICALS, INC. | 2021-11-11 | — | — | US | disclosed |
| CN-113557227-A | Method for producing prostaglandin | 协和医药化工股份有限公司 | 2021-10-26 | — | — | CN | disclosed |
| EP-0916637-A1 | PROCESS FOR PREPARATING OPTICALLY ACTIVE COMPOUNDS | Japan Science and Technology Corporation (JP) | 1999-05-19 | — | — | EP | disclosed |
| EP-0901997-A1 | Process for producing optically active alcohol compound | Takasago International Corporation (JP) | 1999-03-17 | — | — | EP | disclosed |
| US-5780692-A | CATALYTIC ASYMMETRIC HYDROGENATION OF A BENZOPHENONE; SIMPLIFICATION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1998-07-14 | — | — | US | disclosed |
| US-5763688-A | HYDROGENATING A CARBONYL COMPOUND, RUTHENIUM-PHOSPHINE COMPLEX CATALYST, BASE, DIAMINE | RESEARCH DEVELOPMENT CORPORATION OF JAPAN (JP) | 1998-06-09 | — | — | US | disclosed |
| US-5756863-A | Process for preparing optically active cyclohexanol derivatives | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1998-05-26 | — | — | US | disclosed |
| EP-0781749-A2 | Process for producing optically active benzhydrol compounds | Takasago International Corporation (JP) | 1997-07-02 | — | — | EP | disclosed |
| EP-0768288-A2 | Process for preparing optically active cyclohexanol derivatives | Takasago International Corporation (JP) | 1997-04-16 | — | — | EP | disclosed |
| EP-0718265-A2 | Method for producing an alcohol | RESEARCH DEVELOPMENT CORPORATION OF JAPAN (JP) | 1996-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169600-A1 | METHOD FOR PRODUCING PKROSTAGLANDIN | PTGS1, PTGER1, RACK1 | KCNN4 495/4885CYP1A2 472/4885CYP2D6 1210/4885 |
| US-20100311975-A1 | CATIONIC TRANSITION METAL CATALYSTS | AP2M1, OPRM1, CD81 | KCNN4 152/4885CYP1A2 4560/4885CYP2D6 3821/4885 |
| US-12129249-B2 | Method for producing optically active compound | DHPS, QDPR, SPR | KCNN4 1335/4885CYP1A2 1113/4885CYP2D6 484/4885 |
| US-20210347769-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DHPS, QDPR, SPR | KCNN4 1335/4885CYP1A2 1113/4885CYP2D6 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.